Previous 10 | Next 10 |
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Ultragenyx Pharmaceutical Inc. 2020 Q4 - Results - Earnings Call Presentation
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2020 Earnings Conference Call February 11, 2021 05:00 PM ET Company Participants Joshua Higa - Director, Investor Relations Emil Kakkis - Chief Executive Officer and President Camille Bedrosian - Chief Medical Officer Erik Harris - Chief Commercial Off...
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q4 2020 Earnings Call Feb 11, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Ultragenyx Pharmaceutical Inc (RARE) Q4 2020 Earnings Call Tr...
Ultragenyx Pharmaceutical (RARE): Q4 GAAP EPS of -$0.37 beats by $0.79.Revenue of $91.54M (+157.2% Y/Y) beats by $21M.Cash, cash equivalents, and marketable debt securities were $1.2B as of Dec. 31, 2020.Press Release For further details see: Ultragenyx Pharmaceutical EPS beats by $0.79...
2020 total revenue of $271.0 million and 2020 Crysvita 1 revenue to Ultragenyx of $138.9 million 2021 Crysvita 1 revenue in Ultragenyx territories guidance of $180 million to $190 million reaffirmed Strong Dojolvi launch continues with approximately...
Ultragenyx Pharmaceutical (NASDAQ:RARE) is scheduled to announce Q4 earnings results on Thursday, February 11th, after market close.The consensus EPS Estimate is -$1.14 and the consensus Revenue Estimate is $70.54M (+98.2% Y/Y).Over the last 1 year, RARE has beaten EPS estimates 50% of the ti...
NOVATO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, Fe...
Join Emerald’s team of 13 investment professionals and 12 presenting companies on February 4 th as Emerald Asset Management presents the 28 th annual Emerald Groundhog Day Investment Forum, featuring insights and analysis focused on growth-oriented investments in the year...
The FDA has signed off Investigational New Drug application for Ultragenyx Pharmaceutical's (RARE) UX701, an investigational AAV9 gene therapy being evaluated for the treatment of Wilson Disease, a rare inherited disorder characterized by the buildup of copper in the body.Enrollment in a seam...
Clinical trial will utilize a single-protocol Phase 1/2/3 design UX701 manufacturing complete at commercial quality and scale using HeLa PCL technology First patient to be dosed in the first half of 2021 NOVATO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Ph...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...